drugset / Trial / NCT04987242
An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in subjects with hyperuricemia in an inpatient, controlled setting.
Timeline
- Start
- 2021-07-16
- Primary completion
- 2022-03-02
- Completion
- 2022-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALLN-346 | Protein / enzyme biologic | — | Oral |